サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1760906

結核検査の世界市場

Tuberculosis Testing

出版日
ページ情報
英文 423 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=150.05円
結核検査の世界市場
出版日: 2025年07月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 423 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

結核検査の世界市場は2030年までに29億米ドルに達する

2024年に22億米ドルと推定される結核検査の世界市場は、2024年から2030年にかけてCAGR 4.9％で成長し、2030年には29億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである病院は、CAGR 5.3％を記録し、分析期間終了時には14億米ドルに達すると予測されます。医局セグメントの成長率は、分析期間中CAGR 4.4%と推定されます。

米国市場は1億3,860万米ドルと推定、中国はCAGR5.6％で成長予測

米国の結核検査市場は、2024年に1億3,860万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGR 5.6%を牽引し、2030年には3億8,340万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.7%と2.8%と予測されています。欧州では、ドイツがCAGR 3.6%で成長すると予測されています。

世界の結核検査市場- 主要動向と促進要因まとめ

結核は依然として世界の健康上の大きな課題であり、効果的な診断と治療には正確でタイムリーな検査が不可欠です。結核検査には、皮膚検査、血液検査、喀痰検査、分子診断など様々な方法が含まれます。伝統的なマントゥーのツベルクリン皮膚テストが広く用いられてきたが、インターフェロン-γ放出アッセイ（IGRA）や核酸増幅テスト（NAAT）のような、より新しく正確な検査が開発され、診断精度が向上しています。これらの先進的な検査は、より迅速な結果を提供し、皮膚検査で偽陽性を引き起こす可能性のあるBCGワクチン接種前の影響を受けにくいです。

特に発展途上国では、この病気に伴う罹患率や死亡率が高いことから、結核検査の重要性が強調されています。早期かつ正確な発見は、結核の蔓延を抑え、適切な治療を開始するために極めて重要です。分子診断学の革新は、薬剤耐性株を含む結核の検出能力を著しく向上させ、より的を絞った効果的な治療レジメンを可能にしています。また、遠隔地や資源に乏しい環境においても、迅速な診断と治療開始を可能にするポイントオブケア検査機器の普及も進んでいます。

結核検査市場の成長は、いくつかの要因によってもたらされます。特に結核罹患率の高い国々では、結核の有病率が増加しており、効果的な診断ソリューションの必要性が高まっています。迅速な自動検査プラットフォームの開発など、分子診断の技術的進歩により、結核検出のスピードと精度が向上しています。多剤耐性結核（MDR-TB）の増加も、耐性パターンを特定し適切な治療を導くことができる高度な診断検査への需要に拍車をかけています。さらに、WHOや世界エイズ・結核・マラリア対策基金（Global Fund to Fight AIDS, Tuberculosis, and Malaria）などの組織による世界ヘルスへの取り組みや資金援助が、結核検査技術の開発と展開を支援しています。結核検査をHIVスクリーニングなど、より広範な公衆衛生の取り組みと統合することで、診断プログラムの範囲と効果が強化され、市場をさらに牽引しています。

セグメント

検査タイプ（培養ベース検査、胸部X線検査、インターフェロン-ガンマ放出アッセイ（IGRA）、ツベルクリン反応検査（TST）、塗抹顕微鏡検査、核酸検査（NAT）、血清学的検査、その他の検査タイプ）、エンドユーザー（病院、医師事務所、リファレンスラボ、その他のエンドユーザー）

調査対象企業の例（計55社）

  • Akonni Biosystems, Inc.
  • bioMerieux SA
  • Creative Diagnostics
  • CTK Biotech, Inc.
  • DiaSorin SpA
  • Jiangsu Medomics Medical Technology Co., Ltd.
  • NeoGenomics Laboratories, Inc.
  • QIAGEN GmbH
  • Siemens Healthineers AG
  • Takara Bio, Inc.
  • Thermo Fisher Scientific, Inc.
  • ZeptoMetrix LLC

AI統合

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP16869

Global Tuberculosis Testing Market to Reach US$2.9 Billion by 2030

The global market for Tuberculosis Testing estimated at US$2.2 Billion in the year 2024, is expected to reach US$2.9 Billion by 2030, growing at a CAGR of 4.9% over the analysis period 2024-2030. Hospitals, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Physicians Office segment is estimated at 4.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$138.6 Million While China is Forecast to Grow at 5.6% CAGR

The Tuberculosis Testing market in the U.S. is estimated at US$138.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$383.4 Million by the year 2030 trailing a CAGR of 5.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.6% CAGR.

Global Tuberculosis Testing Market - Key Trends & Drivers Summarized

Tuberculosis (TB) remains a major global health challenge, and accurate, timely testing is crucial for effective diagnosis and treatment. Tuberculosis testing involves various methods, including skin tests, blood tests, sputum tests, and molecular diagnostics. The traditional Mantoux tuberculin skin test has been widely used, but newer, more accurate tests like the interferon-gamma release assays (IGRAs) and nucleic acid amplification tests (NAATs) have been developed to improve diagnostic accuracy. These advanced tests provide quicker results and are less affected by prior BCG vaccination, which can cause false positives in skin tests.

The importance of tuberculosis testing is underscored by the high morbidity and mortality rates associated with the disease, particularly in developing countries. Early and accurate detection is critical to controlling the spread of TB and initiating appropriate treatment. Innovations in molecular diagnostics have significantly enhanced the ability to detect TB, including drug-resistant strains, enabling more targeted and effective treatment regimens. Point-of-care testing devices are also becoming more prevalent, allowing for faster diagnosis and treatment initiation in remote and resource-limited settings.

The growth in the tuberculosis testing market is driven by several factors. The increasing prevalence of TB, particularly in high-burden countries, has heightened the need for effective diagnostic solutions. Technological advancements in molecular diagnostics, such as the development of rapid, automated testing platforms, have improved the speed and accuracy of TB detection. The growing incidence of multidrug-resistant TB (MDR-TB) has also spurred the demand for advanced diagnostic tests that can identify resistance patterns and guide appropriate treatment. Additionally, global health initiatives and funding from organizations such as the WHO and the Global Fund to Fight AIDS, Tuberculosis, and Malaria are supporting the development and deployment of TB testing technologies. The integration of TB testing with broader public health efforts, such as HIV screening, further drives the market by enhancing the reach and impact of diagnostic programs.

SCOPE OF STUDY:

The report analyzes the Tuberculosis Testing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Test Type (Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests, Other Test Types); End-Use (Hospitals, Physicians Office, Reference Laboratories, Other End-Uses)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.

Select Competitors (Total 55 Featured) -

  • Akonni Biosystems, Inc.
  • bioMerieux SA
  • Creative Diagnostics
  • CTK Biotech, Inc.
  • DiaSorin SpA
  • Jiangsu Medomics Medical Technology Co., Ltd.
  • NeoGenomics Laboratories, Inc.
  • QIAGEN GmbH
  • Siemens Healthineers AG
  • Takara Bio, Inc.
  • Thermo Fisher Scientific, Inc.
  • ZeptoMetrix LLC

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Tariff Impact on Global Supply Chain Patterns
    • Tuberculosis Testing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
    • Global Market Overview and Outlook
    • Global Tuberculosis Testing Market Exuding High Degree of Vim & Vigor
    • North America Claims Commanding Revenue Share
    • Culture-based Tests & Hospitals: Primary Contributors to Tuberculosis Testing Market
    • Salient Factors Influencing Dynamism of Global Tuberculosis Testing Market
    • Intense Competition Drive Players to Bet on Innovations
    • Molecular Diagnosis Innovations Soaking Up Limelight in the Tuberculosis Testing Arena
    • W.H.O Aims to Improve Access to Rapid Molecular Tests for Diagnosis of TB & Drug-Resistant TB
    • WHO-Endorsed Molecular Platforms & Tests
    • Recent Market Activity
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Global Tuberculosis Efforts to Drive the Market for Tuberculosis Testing
    • Bracing Technological Innovations, Tuberculosis Testing Moves in New Direction
    • Tuberculosis Screening: The Dawn of Artificial Intelligence Technology
    • Nanodiagnostics Set to Witness Growth in TB Testing
    • A Nanobiosensor for Rapid Detection of Mycobacterium Tuberculosis
    • CRISPR-based Biosensing to See Significant Growth in Pediatric Tuberculosis
    • Present Limitations and Future Directions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Culture-Based Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Culture-Based Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 3: World 15-Year Perspective for Culture-Based Tests by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Chest X-Ray by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Chest X-Ray by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 6: World 15-Year Perspective for Chest X-Ray by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Interferon-Gamma Release Assay (IGRA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Interferon-Gamma Release Assay (IGRA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 9: World 15-Year Perspective for Interferon-Gamma Release Assay (IGRA) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Mantoux Test (TST) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Mantoux Test (TST) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 12: World 15-Year Perspective for Mantoux Test (TST) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Smear Microscopy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Smear Microscopy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 15: World 15-Year Perspective for Smear Microscopy by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Nucleic Acid Testing (NAT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Nucleic Acid Testing (NAT) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 18: World 15-Year Perspective for Nucleic Acid Testing (NAT) by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Serological Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Serological Tests by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 21: World 15-Year Perspective for Serological Tests by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Test Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Other Test Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 24: World 15-Year Perspective for Other Test Types by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 27: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Physicians Office by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Physicians Office by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 30: World 15-Year Perspective for Physicians Office by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Reference Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Reference Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 33: World 15-Year Perspective for Reference Laboratories by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 35: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 36: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 37: World Tuberculosis Testing Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Tuberculosis Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Tuberculosis Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Tuberculosis Testing by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: Japan 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 59: China Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: China 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Tuberculosis Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Tuberculosis Testing by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Tuberculosis Testing by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • FRANCE
    • Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: France 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 77: France Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Germany Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Germany 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 83: Germany Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Germany Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Germany 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 86: Italy Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Italy Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Italy 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 89: Italy Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Italy Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Italy 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 92: UK Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: UK Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: UK 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 95: UK Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: UK Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: UK 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 98: Spain Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Spain Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Spain 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 101: Spain Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Spain Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Spain 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 104: Russia Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Russia Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Russia 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 107: Russia Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Russia Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Russia 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of Europe Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Rest of Europe 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 113: Rest of Europe Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Rest of Europe Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Rest of Europe 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Asia-Pacific 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 119: Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Asia-Pacific Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Asia-Pacific 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 123: Asia-Pacific Historic Review for Tuberculosis Testing by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Asia-Pacific 15-Year Perspective for Tuberculosis Testing by Geographic Region - Percentage Breakdown of Value Revenues for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • AUSTRALIA
    • Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 125: Australia Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Australia Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Australia 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 128: Australia Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Australia Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Australia 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 131: India Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: India Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: India 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 134: India Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: India Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: India 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 137: South Korea Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: South Korea Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: South Korea 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 140: South Korea Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: South Korea Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: South Korea 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 143: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Asia-Pacific Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Asia-Pacific 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 146: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Asia-Pacific Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Asia-Pacific 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 149: Latin America Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Latin America Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Latin America 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 152: Latin America Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Latin America Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Latin America 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 155: Latin America Recent Past, Current & Future Analysis for Tuberculosis Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 156: Latin America Historic Review for Tuberculosis Testing by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Latin America 15-Year Perspective for Tuberculosis Testing by Geographic Region - Percentage Breakdown of Value Revenues for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 158: Argentina Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Argentina Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Argentina 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 161: Argentina Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Argentina Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Argentina 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 164: Brazil Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Brazil Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Brazil 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 167: Brazil Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Brazil Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Brazil 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 170: Mexico Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Mexico Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Mexico 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 173: Mexico Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Mexico Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Mexico 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 176: Rest of Latin America Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Rest of Latin America Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Rest of Latin America 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 179: Rest of Latin America Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Latin America Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Latin America 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 182: Middle East Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Middle East Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Middle East 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 185: Middle East Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Middle East Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Middle East 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
    • TABLE 188: Middle East Recent Past, Current & Future Analysis for Tuberculosis Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 189: Middle East Historic Review for Tuberculosis Testing by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Middle East 15-Year Perspective for Tuberculosis Testing by Geographic Region - Percentage Breakdown of Value Revenues for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • IRAN
    • TABLE 191: Iran Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Iran Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Iran 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 194: Iran Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Iran Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Iran 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 197: Israel Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Israel Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Israel 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 200: Israel Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Israel Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Israel 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 203: Saudi Arabia Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Saudi Arabia Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Saudi Arabia 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 206: Saudi Arabia Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Saudi Arabia Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Saudi Arabia 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 209: UAE Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: UAE Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: UAE 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 212: UAE Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: UAE Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: UAE 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 215: Rest of Middle East Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Rest of Middle East Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Rest of Middle East 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 218: Rest of Middle East Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Rest of Middle East Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: Rest of Middle East 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Tuberculosis Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 221: Africa Recent Past, Current & Future Analysis for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Africa Historic Review for Tuberculosis Testing by Test Type - Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: Africa 15-Year Perspective for Tuberculosis Testing by Test Type - Percentage Breakdown of Value Revenues for Culture-Based Tests, Chest X-Ray, Interferon-Gamma Release Assay (IGRA), Mantoux Test (TST), Smear Microscopy, Nucleic Acid Testing (NAT), Serological Tests and Other Test Types for the Years 2015, 2025 & 2030
    • TABLE 224: Africa Recent Past, Current & Future Analysis for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Africa Historic Review for Tuberculosis Testing by End-Use - Hospitals, Physicians Office, Reference Laboratories and Other End-Uses Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: Africa 15-Year Perspective for Tuberculosis Testing by End-Use - Percentage Breakdown of Value Revenues for Hospitals, Physicians Office, Reference Laboratories and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION